What is Aptevo Therapeutics Inc. (APVO)?

Aptevo Therapeutics Inc. (APVO) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of APVO?

The current price of APVO is $1.28. Prices are updated in real time on Stocks360.

What is APVO's price-to-earnings (PE) ratio?

APVO's trailing twelve-month PE ratio is -0.01, based on current price and earnings per share data available on Stocks360.

What is APVO's market capitalization?

APVO's market capitalization is $2,799,177.00, placing it in the small-cap tier.

Aptevo Therapeutics Inc. (APVO)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.28

Market Cap

$2.80M

PE (TTM)

-0.01

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.68

Day Range

$1.25 – $1.58

52-wk Range

$1.25 – $28.44

Avg Volume

N/A

Volume

79.96K

Aptevo Therapeutics Inc. (APVO) is a publicly traded company in the Healthcare sector. Latest price: $1.28. Market cap $2.80M. Trailing PE -0.01. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $26.28 2026-10-27 · $1.28 (-95.13%)

Earnings

Most Recent

Aug 14, 2026

EPS $-5.31 vs est. $-6.01

Beat by $0.70

Next Earnings

Nov 5, 2026

EPS estimate $-3.72

Proprietary Signals

Signal snapshot temporarily unavailable.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Thera…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.01×
P/S (TTM)	0.00×
P/B	0.25×
P/FCF (TTM)	-0.11×
EV / EBITDA	0.11×
EV / Sales	0.00×
Earnings Yield	-1724.50%
Free Cash Flow Yield	-905.37%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$2.79M
Net Income (TTM)	-$48.27M
Free Cash Flow (TTM)	-$25.34M
Net Debt	-$5.59M
Working Capital	$5.61M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-201.49%
Return on Invested Capital	-262.30%